繁體中文
中文繁體中文EnglishFrançaisDeutsch日本語PortuguêsEspañolالعربيةРусскийBahasa IndonesiaไทยTiếng ViệtBahasa Melayu
凱沙夫醫藥 KESHAV
今日優惠 熱賣 購物車 (0)
NEWS DETAIL

Syndax announced SAVE data published in the *Journal of Clinical Oncology* on Revuforj® (revumenib) in combination with decitabine/cidazaril and venetoclax for the treatment of relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML. —GlobeNewswire

Syndax announced that it has published SAVE data in the *Journal of Clinical Oncology* on Revufo…

Medical Information

该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

文章相關商品

系統已根據文章標題、摘要和正文，自動匹配目前在售的強相關藥品。

盧修斯 Revumenib 線上購買

盧修斯 Revumenib 線上購買

TWD 8,027 – TWD 42,427價格範圍：TWD 8,027 到 TWD 42,427
FDA 標籤品種：Revuforj。 活性成分/通用名：REVUMENIB。 上市企業：Syndax Pharmaceuticals, Inc.。 給藥途徑：ORAL。 主要適應症：1 INDICATIONS AND USAGE REVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) transloop test 相機year and older. ( 1 ) the t
查看商品
維奈托克錠 VECLADX Venetoclax 100mg

維奈托克錠 VECLADX Venetoclax 100mg

TWD 7,167
維奈托克（Venetoclax，又譯為：維奈妥拉）是一種全世界首創的選擇性標靶b細胞淋巴瘤-2(BCL-2)蛋白的藥物。在某些血癌或其他癌症中，BCL-2起到了至關重要的作用，它可以阻止癌細胞的死亡（細胞凋亡），而維奈托克則是可以透過阻斷BCL-2蛋白來恢復凋亡過程。維奈托克旨在選擇性抑制BCL-2的功能，恢復細胞的通訊系統，讓癌細胞自我毀滅，達到治療腫瘤的目的。
查看商品

常見問題

Which products are related to this article?

The system matched these relevant products from the article content: 盧修斯 Revumenib 線上購買、盧修斯 維奈托克 Venetoclax 線上購買、維奈托克錠 VECLADX Venetoclax 100mg.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp 微信 微信